Overview

Growth Hormone Deficiency in Adults (GHDA)

Status:
Completed

Trial end date:
2005-01-24

Target enrollment:

Participant gender:

Summary

This trial is conducted in Japan. The aim of this trial is to demonstrate superiority of the effect of NN-220 compared with that of placebo as assessed by the change in percent in truncal fat (kg) from baseline to 24 weeks' treatment (end of treatment) in patients with Growth Hormone Deficiency in Adults (GHDA).

Phase:

Phase 3

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Hormones